Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Roluperidone Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Minerva Neurosciences Forms Advisory Board For Roluperidone
    Minerva Neurosciences Forms Advisory Board For Roluperidone

    01 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/01/3304700/32445/en/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs.html

    GLOBENEWSWIRE
    01 Jun 2026
    Share Share
    Minerva Neurosciences Reports Q1 2026 Financials And Business
    Minerva Neurosciences Reports Q1 2026 Financials And Business

    05 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/05/3287601/32445/en/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates.html

    GLOBENEWSWIRE
    05 May 2026
    Share Share
    Minerva Neurosciences Launches Global Phase 3 Roluperidone Trial
    Minerva Neurosciences Launches Global Phase 3 Roluperidone Trial

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3266016/32445/en/Minerva-Neurosciences-Announces-First-Patient-Screened-in-Global-Phase-3-Confirmatory-Trial-of-Roluperidone-for-the-Treatment-of-Negative-Symptoms-of-Schizophrenia.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    Minerva Neurosciences Reveals Roluperidone-Olanzapine Safety
    Minerva Neurosciences Reveals Roluperidone-Olanzapine Safety

    25 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/25/3262573/32445/en/Minerva-Neurosciences-Presents-Data-from-its-Open-label-Safety-Trial-Evaluating-Roluperidone-Co-administered-with-Olanzapine-at-SIRS-2026.html

    GLOBENEWSWIRE
    25 Mar 2026
    Share Share
    Minerva Neurosciences Hosts Virtual KOL Event On Roluperidone
    Minerva Neurosciences Hosts Virtual KOL Event On Roluperidone

    26 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/26/3225490/32445/en/Minerva-Neurosciences-to-Host-Virtual-KOL-Event-to-Discuss-Roluperidone-From-Unmet-Need-to-Reality-Potentially-the-First-Treatment-for-Patients-with-Negative-Symptoms-of-Schizophre.html

    GLOBENEWSWIRE
    26 Jan 2026
    Share Share
    Minerva Neurosciences Secures $200M To Advance Roluperidone
    Minerva Neurosciences Secures $200M To Advance Roluperidone

    21 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/21/3170126/32445/en/Minerva-Neurosciences-Announces-Financing-of-up-to-200-Million-to-Advance-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Patients-with-Schizophrenia-Through-a-Phase-3-Confi.html

    GLOBENEWSWIRE
    21 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.